SANUWAVE Health Appoints A. Michael Stolarski to its Board

4/19/16

ALPHARETTA, Ga., April 19, 2016 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV)today announced the appointment of A. Michael Stolarski to the Company’s Board of Directors. Mr. Stolarski has 20 years of experience at multiple levels in the orthopedic, podiatric and urologic shockwave market, including positions within business development and finance. With this appointment, the Company’s Board has four members.

“We are delighted to welcome Mike to our Board of Directors,” said Kevin A. Richardson II, CEO and Chairman of the Board of Directors of SANUWAVE Health, Inc. “Mr. Stolarski has developed a strong network of doctors and hospital facilities with the Company’s predecessor device, the OssaTron®. His industry knowledge and strong relationships with doctors and facilities who have adopted the use of shockwave technology will be of great value to SANUWAVE. We look forward to benefiting from his insight as we work to commercialize the dermaPACE® upon FDA approval and advance the Company to the achievement of our current goals.”

Mr. Stolarski founded Premier Shockwave, Inc. in October 2008 and has since served as its President and CEO. Previously, Mr. Stolarski served as the Vice President of Business Development and Acting CFO of SANUWAVE, Inc., President of the Orthopedic Division and Vice President of Finance for HealthTronics Surgical Services, Inc. and CFO and Controller of the Lithotripsy Division of Integrated Health Services, Inc. He holds a MS in Finance from Loyola College, Baltimore and a BS in Accounting and a BS in Finance from the University of Maryland, College Park.

Commenting on his appointment, Mr. Stolarski said, “I am very excited to join SANUWAVE’s Board of Directors at this pivotal time. SANUWAVE represents a compelling growth opportunity with the results of the dermaPACE Phase III clinical trials and the on-going use of the dermaPACE and orthoPACE devices outside of the United States. I look forward to working with the management team to commercialize the dermaPACE device, once FDA approval has been received, as well as expanding the international distribution of their medical devices.”

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE®technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.